R

obyn Karnauskas’s biotech blue skies have turned dark and stormy.

During the biotech boom-boom years, Citi’s large-cap biotech analyst earned a reputation for being eternally sunny. To Karnauskas, every drug was a blockbuster. Buy ratings were bountiful. Price targets moved in only one direction: up.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Wow – Porges writes. “We don’t see this uncertainty lifting in 2018, and possibly not ever.” Should I keep my subscription?

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

X